3D Systems Corporation (DDD) successfully retired $88 million in debt on June 24, 2025, restructuring with new notes and share repurchases to enhance financial flexibility. On June 26, 2025, their 3D bioprinted nerve repair device, developed with TISSIUM, received FDA approval, solidifying their position in regenerative medicine.

With a focus on additive manufacturing and healthcare, 3D Systems Corporation (DDD) leverages AI-driven software to deliver precision solutions for aerospace, healthcare, materials, and bioprinting industries. Their recent FDA approval for a bioabsorbable nerve repair device further cements their reputation in the field.

3D Systems Corporation (DDD) is recognized as one of the 10 best AI stocks to buy under $3, showcasing their potential for growth and innovation in the additive manufacturing sector. While DDD offers investment potential, other AI stocks may present greater upside and lower risk, as highlighted in a free report on short-term AI stocks.

Read more at Yahoo Finance: 3D Systems Corporation (DDD) Retires $88 Million in Debt; Its 3D bioprinted, bioabsorabable Nerve Repair Device Receives FDA Approval